In spite of the great amount of anti-smoking education,1 there is still 29% of all people in the United States who continue to smoke2 and 47.3% in Japanese men3 although the number has decreased gradually. The psychoactive component of tobacco is nicotine which affects the central nervous system. Nicotine is believed to produce its positive reinforcing and addictive properties by activating the dopaminergic pathway projecting from the ventral tegmental area to the cerebral cortex and the limbic system.
The fourth edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) lists three nicotine-related disorders; nicotine dependence, nicotine withdrawal, and nicotine-related disorder not otherwise specified.2 Several recent studies have suggested a genetic predisposition toward nicotine dependence, and several specific genes related to nicotine dependence have been identified. Major studies regarding the candidate genes and tobacco addiction in the second half of the 1990's were shown in Table  1 .
In addition, patients with mental illness, such as schizophrenia, manic depression, posttraumatic stress disorder (PTSD), and attention-deficit hyperactivity disorder (ADHD), have a higher incidence of smoking than the general population and are the major consumers of tobacco products. 4 Especially, it is considered that almost 90% of outpatients with schizophrenia smoke.2 The recent development of molecular biology regarding genetic influences on schizophrenia or other major mental disorders has provided some evidence for the involvement of a number of specific genes although the results are not necessarily consistent. 5.6 Interestingly, some genes which are considered to be associated with these mental disorders overlap with those which are connected with nicotine dependence (e.g. the D2 dopamine receptor (DRD2) gene). Genetic difference is known for substances in tobacco smoke absorption, their metabolism and for their interactions with receptors. In this paper, we discuss the relationship between smoking behavior and mental disorders, with special emphasis on dopamine receptor genes, transporter genes (serotonin and 
Definition of Nicotine Dependence
The widely used generic criteria for drug dependence are the DSM-IV criteria and the World Health Organization International Statistical Classification of Diseases and Related Health Problems (ICD)-10 criteria. The DSM-IV criteria are generally much more detailed than ICD-10, but share common concepts of difficulty in controlling the use of the drug, of giving priority to drug use over other important obligations, to continued use of the drug in the knowledge of harmful consequences, and tolerance to the effects of the drug. The criteria are designed to apply generically to substance abuse, but provide a suitable framework for determining the addictive or dependent nature of nicotine and smoking. Nicotine dependence is the most prevalent (20% lifetime prevalence)7 and most deadly (50% die from complications)' of the disorders listed in the DSM-IV and ICD-10.
The DSM-IV diagnosis of nicotine dependence requires a minimum of three of seven diagnostic symptoms: tolerance (needing more of the substance to get the same effect or having less effect with repeated use of the same amount of substance), withdrawal (subjective and/or objective changes in the person when the substance is stopped), greater use than intended, persistent desire to quit, great amounts of time spent smoking, activities given up or reduced due to smoking, and continued smoking despite knowledge of having a persistent physical or psychologic problem with the substance. The vast majority of cigarette smokers are daily smokers and, of these, the majority are nicotine-dependent smokers by DSM-IV criteria.9
Questionnaire methods have also been used extensively to measure nicotine dependence. Probably the most widely used is the Fagerstrom Test for Nicotine Dependence (FIND). The FIND, further refined version of the Fagerstrom Tolerance Questionnaire, assesses nicotine dependence (Appendix) . 10 The total score ranges from 0 to 10 and the average score in representative samples of smokers is usually around 3. A maximum of 10 points can be reached, which would mean severest dependence, a score below 5 is generally considered mild, 5-6 moderate and at least 7 severely dependant. This scale can be used in a clinical setting, using the score of FIND as a guide.
The FIND may provide a stronger measure of physical dependence, while the DSM may tap other domains such as awareness of dependence, behaviors resulting from that awareness, and psychiatric symptomatology. Although the FIND and the DSM may appear to measure different aspects of the tobacco dependence process,11 the term 'nicotine dependence' in this review has been used in case of satisfiying either the diagnostic criteria or the questionnaire.
Twin Study: The Evidence for Genes Involved in Smoking Behavior
Initial support for a genetic influence on the use of tobacco came from cross-sectional studies in twins and showed a mean heritability (that is, the proportion of phenotypic variation attributed to genetic variation) of cigarette smoking of 0.53 (range, were not replicated in another subsequent study using non-volunteer white community sample.80 These candidate genes studies need to be repeated in larger sample.
Genes of Nicotine Metabolizing Enzymes
Considerable inter-individual variability exists in the metabolism of nicotine.81 Nicotine is absorbed quickly (in seconds) throughout the body on initial dosing82,83 and then is eliminated with a half-life of 2-3 hours.84 Nicotine is metabolized principally (approximately 80 %) to cotinine by cytochrome P450 (CYP) 2A6,85-87 which is also responsible for much of the metabolism of cotinine.88 CYP2A6 activity varies approximately 50-fold and the basis for constitutive differences in activity has been associated with variant CYP2A6 alleles encoding inactive enzyme.89-91 A statistically significantly reduced frequency of two CYP2A6 null alleles in nicotine-dependent smoking-patients versus never nicotine-dependent individuals and a statistically significant inverse association with the number of cigarettes smoked per week have been reported.91 After the initial report, there have been several non-replications, and the suggestions that the original results were technically in error producing much higher rates of the null allele than exist in reality.
Nicotine is in part metabolized by CYP2D6.92 Phenotyping analyses have indicated that the ratio between the parent compound debrisoquine and the primary metabolite 4-hydroxydebrisoquine varies 10,000-fold in the Caucasian population.93 Some studies suggest that personality characteristics may differ by CYP2D6 genotype and/or the phenotype and it has been hypothesized that an endogenous neuroactive substance involved in dopamine neurotransmission may be a substrate of CYP2D6 in brain.94-96 Furthermore, more than 30 commonly prescribed drugs such as tricyclic antidepressants, neuroleptic, lipophylic -blockers, morphine related drugs and some antiarrhythmics (class IC) are substrates for CYP2D6. 96 As the effect of CYP2D6 activity might rise with increasing tobacco consumption, the effect of tobacco smoking on given diseases might rise with increasing CYP2D6 activity.
Schizophrenia and Smoking Behavior
It has been reported that prevalence of smoking among schizophrenic patients is extraordinary high (70% or greater), and that schizophrenic inpatients are more likely to be smokers than are persons in general population or even other chronic psychiatric inpatients after correcting for other factors. 98 The reason why so many schizophrenic patients smoke was attributed in part to the ability of nicotine to reduce extraordinary sensitivity to outside sensory stimuli and to increase concentration in such patients.2 Nicotine administration also normalizes several sensory-processing deficits seen in this disease. Animal models of sensory deficits have been used to identify specific nicotine receptor subunits that are involved in these brain pathways, indicating that the a7 nAChR subunit may play a role.4 Genetic linkage in schizophrenic families also supports a role for the a7 subunit with linkage at the a7 locus on chromosome 15. 4 To search for evidence of the genetic loci regarding schizophrenia, both candidate gene and genome-wide linkage studies have been in clinical cohorts collected from a variety of populations. Collectively, these works provide some evidence for the involvement of a number of specific genes such as DRD2, DRD3, DRD4 gene, or serotonin type 2a receptor (5HTR-2a) gene, although these data provide suggestive, but no conclusive evidence for causative genes.5 As has been described above, these genes are considered to be associated with smoking behavior. Some of these genes may be also connected with the strong relationship between smoking and schizophrenia.
However, the relationship between smoking and schizophrenia should be explained not only by the genetic factors but also by the 
PERSPECTIVES
Behavioral genetics research has shown that individual differences in smoking behavior are substantially heritable. Twin and familial studies have shown that the genetic factors involved in the initiation and cessation of smoking are partially overlapping but mostly independent. A larger number of candidate genes for smoking behavior have been identified to date.
Of particular interests are studies on smoking behavior and genes that code for those drug-metabolizing enzymes and geneenvironmental interactions as well as studies on lung cancer and metabolic polymorphisms.106 As shown in Table 1 , data regarding correlations between smoking prevalence and polymorphisms in CYP2A6 and CYP2D6 enzymes are limited. The molecular epidemiologic studies of mental disorders that have been carried out to date have rarely looked at a variety of potential gene-environmental interactions, explored associations and interactions with more than one genetic polymorphism107 or gender differences.108 Because many mental disorders which are represented by schizophrenia are multifactorial diseases, the high coincidence between tobacco addiction and several mental disorders should be reconsidered from this point of view. In order to avoid some of the problems associated with molecular epidemiologic studies, Todd109 has addressed the issue of guidelines for the interpretation of results from those studies of multifactorial diseases. They expect that those studies should contain large sample size, an independent replication followed by initial study, biological plausibility and physiologically meaningful data supporting a functional role of the polymorphism in question. The initial studies showed a substantially increased/decreased risk of developing lung cancer in individuals with specific genotypes.
Rapid advances in high-throughout gene analysis by DNA chip technology will spread up the identification of new mutations in the genes of predisposing smoking. The main task, however, will be to characterize the functional significance of these gene variants in humans. Such efforts are under way, e.g., the Human Genome Project by Human Genome Organisation, which will come to its completion in the near future, or the Environmental Genome Project pursued by the National Institute for Environmental Health Services in the United States."' Although allelic association is powerful method for detecting quantitative genetic influences on complex traits such as cigarette smoking, there are limitations to such studies. First, it is not yet clear whether the association with given polymorphisms are due to modifications of those polymorphisms or to linkage disequilibrium with some other polymorphisms. Second, allelic association can arise as a result of population stratification as well as genuine transmission. Therefore, polymorphisms stated here are some of many different factors, both genetic and environmental, that influence smoking behavior. A fuller understanding of the genetics of cigarette smoking behavior will lead to the clarification of the relationship between those mental disorders and smoking behavior. 
